Showing results (291-300 of 324) with videos related to

Sort By:
Pageof 33
Plos One|March 15, 2024
Walkability and socio-economic status in relation to walking, playing and sports practice in a representative Spanish sample of youth: The PASOS studySusana Aznar, Fabio Jimenez-Zazo, Cristina Romero-Blanco, et al.
Gastroenterologia Y Hepatologia|December 8, 2019
Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infectionAdrian G McNicholl, Ana Garre, Laura Llorca, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
The American Journal of Gastroenterology|June 23, 2026
Dupilumab for Eosinophilic Esophagitis in Adolescents and Adults: Real-World Outcomes Across Different Dosing Regimens from the EoE CONNECT RegistryEmilio J Laserna-Mendieta, Victoria Úbeda-Vargas, Edurne Amorena, et al.
Pageof 33